A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)

Trial Profile

A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms OSAKA-LCSG1302
  • Most Recent Events

    • 31 Mar 2017 Status changed from recruiting to discontinued.
    • 03 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top